Indications |
Oral Hypertension Adult: Initially, 50-100 mcg tid. As modified-release preparation: 50-100 mcg once or twice daily. Max: 2400 mcg daily. Child: 2-18 yr: Initially 0.5-1 mcg/kg tid, increase gradually if necessary. Max: 25 mcg/kg daily in divided doses (not exceeding 1.2 mg daily). Renal impairment: Supplemental doses after haemodialysis are not necessary.
Oral Prophylaxis of migraine Adult: 50 mcg bid increased to 75 mcg bid if no remission after 2 wk. Renal impairment: Supplemental doses after haemodialysis are not necessary.
Oral Menopausal flushing Adult: 50 mcg bid increased to 75 mcg bid if no remission after 2 wk. Renal impairment: Supplemental doses after haemodialysis are not necessary.
Transdermal Hypertension Adult: Apply a patch once wkly, delivering 100-300 mcg of clonidine base daily at a constant rate. Renal impairment: Supplemental doses after haemodialysis are not necessary.
Intravenous Hypertensive crisis Adult: 150-300 mcg by slow inj over 10-15 min. Max: 750 mcg over 24 hr. Child: 2-18 yr: 2-6 mcg/kg as a single dose. Max: 300 mcg. Renal impairment: Supplemental doses after haemodialysis are not necessary.
Epidural Severe cancer pain Adult: Initially, 30 mcg/hr as continuous infusion in combination with an opioid, adjusted according to patient's response. |
||||||||||||||||||||
Contraindications |
Hypersensitivity. Disorders of cardiac pacemaker activity and conduction. Pregnancy and lactation. | ||||||||||||||||||||
Warnings / Precautions |
Withdraw gradually, renal impairment, tasks that require mental alertness. Cerebrovascular disease, ischaemic heart disease, MI. IV inj should be administered slowly. Occlusive peripheral vascular disorders, history of depression. | ||||||||||||||||||||
Adverse Reactions |
Dry mouth, drowsiness, dizziness, headache, constipation, impotence, vivid dreams, urinary retention; dry, itching, burning sensation in the eye; fluid or electrolyte imbalance, GI upset, paralytic ileus, orthostatic hypotension, weakness, sedation, pruritus, myalgia, urticaria, nausea, insomnia, arrhythmias, agitation. Reduced GI motility at times may cause paralytic ileus. Potentially Fatal: Transient hypertension or profound hypotension, respiratory depression, convulsion. Clonidine withdrawal syndrome could be life threatening. Bradycardia, coma and disturbances in conduction (in individuals with preexisting diseases of SA/AV nodes, overdose or on digitalis). |
||||||||||||||||||||
Overdose Reactions |
Symptoms include profound hypotension, transient hypertension, weakness, vomiting, irritability, diminished or absent reflexes, tiredness, somnolence, drowsiness, deep sedation, irritability, skin pallor, hypothermia, decreased or irregular heart rate, dry mouth, constricted pupils with poor reaction to light, respiratory depression, hypoventilation, dysrhythmias, apnoea, coma, and seizures. May be treated by gastric lavage using activated charcoal and/or cathartic agents. Treatment is usually supportive and symptomatic, with an adequate airway established and maintained since respiratory depression or apnoea may follow. Supportive care may include atropine sulfate for bradycardia, IV fluids and/or vasopressor agents for hypotension, and vasodilators (IV furosemide, diazoxide or phentolamine) for hypertension. Naloxone may be useful for the management of respiratory depression, hypotension, and/or coma. Monitor BP for paradoxical hypertension. Seizures may be controlled with IV benzodiazepine (e.g. diazepam). Haemodialysis is of limited value as only 5% of circulating drug is removed. | ||||||||||||||||||||
Drug Interactions |
Hypotensive action may be potentiated by diuretics and vasodilators. Effects of clonidine antagonised by TCAs and centrally-acting alpha-blockers. May enhance toxicity due to digitalis, lithium. May antagonise oral hypoglycaemics. Potentially Fatal: Hypnosedatives, antihistamines and alcohol may cause excessive drowsiness in patients on clonidine. Withdrawal of clonidine in patients receiving noncardioselective β-blockers may result in rebound BP. Acute severe hypotension following concomitant administration of clonidine and chlorpromazine or haloperidol. See Below for More clonidine Drug Interactions |
||||||||||||||||||||
Lab Interactions |
Transient abnormalities in liver function tests. | ||||||||||||||||||||
Mechanism of Actions |
Clonidine stimulates alpha-2 receptors in brain stem which results in reduced sympathetic outflow from the CNS and a decrease in peripheral resistance leading to reduced BP and pulse rate. It does not alter normal haemodynamic response to exercise at recommended dosages. Onset: 2-3 days (transdermal). Duration: Maintained for 8 hr after removal of system (transdermal). Absorption: Well absorbed from the GI tract (oral); peak plasma concentrations after 3-5 hr. Absorbed from the skin (transdermal). Distribution: 20-40% protein bound. Metabolism: Hepatic: 50% of the dose. Excretion: Via urine within 24 hr (as 40-60% as unchanged drug), via faeces (20% of the dose); 6-24 hr (elimination half-life), prolonged to 41 hr in renal impairment. |
||||||||||||||||||||
Administration |
May be taken with or without food. |
||||||||||||||||||||
Storage Conditions |
Epidural: Store below 30°C. Intravenous: Store below 30°C. Oral: Store below 30°C. Transdermal: Store below 30°C. | ||||||||||||||||||||
ATC Classification |
C02AC01 - clonidine ; Belongs to the class of imidazoline receptor agonists, centrally-acting antiadrenergic agents. Used in the treatment of hypertension. N02CX02 - clonidine ; Belongs to the class of other antimigraine preparations. S01EA04 - clonidine ; Belongs to the class of sympathomimetics used in the treatment of glaucoma. |
||||||||||||||||||||
Storage |
Epidural: Store below 30°C. Intravenous: Store below 30°C. Oral: Store below 30°C. Transdermal: Store below 30°C. | ||||||||||||||||||||
Available As |
|
Clonidine
Post Review about Clonidine Click here to cancel reply.
Clonidine Containing Brands
Clonidine is used in following diseases
Drug - Drug Interactions of Clonidine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.